



The Board of Directors
Shanghai Fosun New Medicine Research Company Limited (上海復星新藥研究股份有限公司) (the “Offeror”)

The Board of Directors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (上海復星醫藥(集團)股份有限公司)
(“Fosun Pharma”)
Building A
No. 1289 Yishan Road
Shanghai, 200233, China

23 December 2024

Dear Sirs,

Proposed privatisation of Shanghai Henlius Biotech, Inc. (stock code: 02696) (the “Company”) by the Offeror by way of merger by absorption of the Company and withdrawal of listing of the H shares of the Company

We, China International Capital Corporation Hong Kong Securities Limited, refer to the composite document dated 23 December 2024 jointly issued by the Offeror, Fosun Pharma and the Company in relation to the captioned matter (the “**Composite Document**”). Unless otherwise defined herein, terms used in this letter shall have the same meanings as defined in the Composite Document.


We hereby give, and confirm that we have not withdrawn, our written consent to the issue of the Composite Document with the references to our name, logo, qualifications and/or letter in the form and context in which they respectively appear in the Composite Document.

We hereby confirm that we have given and have not withdrawn our consent to a copy of this consent letter and the letter as set out in Appendix V to the Composite Document being made available for inspection as described in the section headed “11. Documents on Display” in Appendix IV to the Composite Document.

[The remainder of this page is deliberately left blank]

Yours faithfully,

For and on behalf of
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED

A handwritten signature in black ink, appearing to read 'David Ching', is written over a horizontal line.

Name: David CHING

Title: Executive Director